News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
ANVISA issues CGMP to Concord Biotech’s Unit I
Acquisition of exclusive commercialization rights for European markets
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
VeerHealth Care will be raising Rs. 8 crores through bank borrowings
Subscribe To Our Newsletter & Stay Updated
